MOXILASE CV-ES

The 600mg + 42.9mg Dry-Syrup Combination, Explained

MOXILASE CV-ES w/w is a fixed-dose dry-syrup formulation containing Amoxycillin 600mg + Potassium Clavulanate 42.9mg. The product is presented in a 50ml glass bottle, with strawberry flavour and monocarton packaging.

The formulation brings together an antibacterial agent and a beta-lactamase inhibitor in a single oral-suspension presentation. It is intended for use when this antibiotic combination is considered suitable by a healthcare professional.

 FORMULATION PROFILE

WHAT CAN THIS FORMULATION BE USED FOR?

When a bacterial infection is confirmed or strongly suspected, the prescribing professional may consider an amoxycillin + clavulanate combination for appropriate susceptible infections.

1️⃣ Respiratory Care

Used for selected susceptible bacterial infections involving the respiratory tract.

2️⃣ Ear & Sinus Infections

May be prescribed for certain bacterial infections affecting the ear or sinuses.

3️⃣ Urinary Infections

Can be considered for selected susceptible bacterial urinary tract infections.

4️⃣ Skin & Soft-Tissue Infections

May be prescribed for appropriate bacterial infections involving skin and soft tissues.

5️⃣ Other Susceptible Infections

The final choice depends on the infection, suspected organism, patient factors, and clinical judgment.

Antibiotics should not be used simply because symptoms resemble an infection.

WHY TWO ACTIVE INGREDIENTS?

MOXILASE CV-ES w/w uses a combination approach.

Amoxycillin works against susceptible bacteria by interfering with bacterial cell-wall formation.

Certain bacteria can produce beta-lactamase enzymes, which can break down some penicillin antibiotics. Potassium Clavulanate inhibits certain of these enzymes, helping preserve the activity of amoxicillin against susceptible organisms.

A Simple Breakdown

AMOXYCILLIN 600mg
↓
Targets susceptible bacteria

POTASSIUM CLAVULANATE 42.9mg
↓
Inhibits certain beta-lactamase enzymes

COMBINATION
↓
Supports antibacterial activity against appropriate susceptible organisms

FROM DRY POWDER TO ORAL SUSPENSION

The product is supplied as a dry syrup, so it needs to be prepared before administration.

The exact quantity of water, preparation method, storage conditions, and use-after-reconstitution period should always be taken from the approved product packaging or product insert.

Administration Checklist

• Prepare as directed — Follow the product-specific instructions.

• Measure correctly — Use the recommended measuring device.

• Mix properly — Shake according to the product directions.

• Follow the prescription — Maintain the advised dose and frequency.

• Complete treatment as directed — Do not independently stop or extend therapy.

• Store appropriately — Follow the approved storage instructions.

⚠️ DOSE REMINDER

Pediatric doses should be prescribed according to individual patient factors and should never be self-calculated.

WHAT SHOULD YOU EXPECT FROM TOLERABILITY?

As with other medicines, some individuals may experience side effects while using MOXILASE CV-ES w/w.

Serious or rapidly worsening symptoms require prompt medical evaluation.

FIVE THINGS TO CHECK FIRST

1. Allergy

Previous reactions to penicillins, cephalosporins, or related antibiotics should be reported.

2. Kidney Health

Inform the healthcare professional about existing kidney problems.

3. Liver History

Previous liver disease or antibiotic-associated liver reactions should be disclosed.

4. Previous Antibiotic Reactions

Tell the prescriber about any serious reaction to antibiotic treatment.

5. Responsible Antibiotic Use

Never use leftover antibiotics, share the medicine, or alter treatment without medical guidance.

MAKE MOXILASE CV-ES w/w PART OF YOUR NEXT GROWTH STORY

A strong pharma portfolio starts with the right products. MOXILASE CV-ES w/w, containing Amoxycillin 600mg + Potassium Clavulanate 42.9mg Dry Syrup, comes in a 50ml strawberry-flavoured glass bottle with monocarton packaging, a formulation presentation designed for a focused pharmaceutical portfolio.

YOUR NEXT PHARMA CHANNEL

MONARK BIOCARE brings multiple routes for pharma businesses:

• PCD Pharma Franchise — Develop your presence across selected territories.

• Third Party Manufacturing — Build products through an outsourced manufacturing model.

• Ethical Promotion — Create professional-focused product outreach.

• Export Medicines — Explore eligible international pharmaceutical markets.

• Private Label Manufacturing — Develop products under your own brand.

• Contract Manufacturing — Explore scalable manufacturing partnerships.

• Distribution & Institutional Supply — Expand your pharmaceutical supply network.

WHERE WILL YOU TAKE IT NEXT?

From MOXILASE CV-ES to a wider pharmaceutical portfolio, Monark Biocare provides business-oriented partnership opportunities designed around your growth direction.

Explore the product. Explore the partnership. Build your next pharma opportunity with Monark Biocare.

Disclaimer

This content is for general educational and product-information purposes only. MOXILASE CV-ES w/w should be used under appropriate medical supervision. Always follow the approved product information and professional advice for dosage, preparation, storage, indications, and treatment duration.

FAQs: ANSWERS IN 5

01. What is the composition of MOXILASE CV-ES w/w?

It contains Amoxycillin 600mg + Potassium Clavulanate 42.9mg in a dry-syrup formulation.

02. What does clavulanate do?

It inhibits certain beta-lactamase enzymes, helping protect amoxycillin against enzymatic breakdown by susceptible bacteria.

03. Why is it supplied as a dry syrup?

The dry-syrup format allows the product to be prepared as an oral suspension according to the approved product instructions.

04. What is the pack size?

MOXILASE CV-ES w/w is supplied in a 50ml glass bottle, with strawberry flavour and monocarton packaging.

05. Can the dose be decided without a prescription?

No. The appropriate dose, particularly for children, should be determined by a healthcare professional based on relevant patient and infection-specific factors.